Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA Facility Fees Should Be Waived Until First ANDA Approved, Petition Argues

Executive Summary

Bangladesh-based Square Pharmaceuticals says the fees are burdensome for first-time filers, given long approval times, but the firm’s citizen petition strategy may further delay approval of its ANDA.

You may also be interested in...



FDA Says It’s The Law, Denies Petition Requesting GDUFA Fee Payment Changes

The agency also says only Congress could enact fee waivers and exemptions, but Square Pharmaceuticals indicates it will join lobbying efforts to create them.

GDUFA Grace Period For Facility Fees Appears To Be Over

FDA’s drastically expanded arrears list for FY 2014 fees totals more than 100 generic drug facilities; more than 40 still owe the FY 2013 fee.

FDA Generics Director’s Departure Shows Why Chemistry Matters

Another outside candidate is expected to eventually take over for the departing director Gregory Geba, and while the Office of Generic Drugs can run smoothly without a permanent leader for now, it cannot do so forever.

Related Content

Topics

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel